EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world evaluation of the positive predictive value and transmission burden of a novel implantable cardiac monitor with a remote reprogramming capability: insights from a single-center experience

Samir Fareh, Paul Charles, Emilie Said, Monica Campari, Sergio Valsecchi, Mathieu Montoy

Frontiers in Cardiovascular Medicine · 20.11.2026 · 13

DOI: 10.3389/fcvm.2026.2008276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 20.11.2026. Verfasst von Samir Fareh und 5 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Implantable cardiac monitors (ICMs) are widely used for long-term arrhythmia surveillance but are often limited by a high false-positive alert rate, increasing the workload for device clinics. The LUX-Dx™ ICM incorporates dual-stage detection algorithms and remote reprogramming features designed to improve diagnostic accuracy and workflow efficiency.

Objective

To assess the real-world performance of the LUX-Dx™ ICM across all detectable arrhythmias, evaluating positive predictive value (PPV), transmission burden, and the impact of remote reprogramming.

Methods

We retrospectively analyzed 133 consecutive patients who received a LUX-Dx™ ICM between July 2023 and October 2024 with follow-up data collected through June 2025. Device episodes and transmissions were reviewed over a median 13-month follow-up. PPV was calculated at both patient- and episode-levels. Changes in PPV before and after remote reprogramming were also assessed.

Results

A total of 55,064 episodes and 5,192 transmissions were recorded (4.0 episodes and 1.2 transmissions per patient-month). Overall patient-level PPV was 87% (110/126), highest for bradycardia (100%) and lowest for pauses (71%). Overall, 93 of 126 patients (74%) with adjudicated episodes had at least one false-positive detection during follow-up. Episode-level PPV was 82% (95% CI: 82−83). Remote reprogramming was performed in 34% of patients and was associated with a descriptive increase in episode-level PPV (from 77% to 87%). Review strategies focusing on the first, longest, or fastest episode per transmission yielded comparable PPVs.

Conclusions

In routine clinical practice, the LUX-Dx™ ICM demonstrated favorable positive predictive value. Remote reprogramming enabled individualized optimization of detection parameters, although its potential impact on detection performance requires further investigation.

Zitieren

APA

Fareh, S., Charles, P., Said, E., Campari, M., Valsecchi, S., & Montoy, M. (2026). Real-world evaluation of the positive predictive value and transmission burden of a novel implantable cardiac monitor with a remote reprogramming capability: insights from a single-center experience. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.2008276

Vancouver

Fareh S, Charles P, Said E, Campari M, Valsecchi S, Montoy M. Real-world evaluation of the positive predictive value and transmission burden of a novel implantable cardiac monitor with a remote reprogramming capability: insights from a single-center experience. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.2008276

BibTeX
@article{Fareh2026,
  author = {Fareh, Samir and Charles, Paul and Said, Emilie and Campari, Monica and Valsecchi, Sergio and Montoy, Mathieu},
  title = {Real-world evaluation of the positive predictive value and transmission burden of a novel implantable cardiac monitor with a remote reprogramming capability: insights from a single-center experience},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.2008276}
}
Kostenlos starten →